t
Arecor Therapeutics plc announced on 29 April 2024 that its final results for the year ended 31 December 2023 will be published on Tuesday, 7 May 2024. On the same day, Chief Executive Officer Sarah Howell and Chief Business Officer Manjit Rahelu will host an in-person briefing for analysts, which will also be available via live webcast and conference call.
| Date | 29 Apr 2024 |
| Time | 07:00:12 |
| Category | Results |
| ID | 3113M |
Arecor Therapeutics plc
("Arecor" or the "Group")
NOTICE OF RESULTS
Cambridge, UK, 29 April 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, will announce its final results for the year ended 31 December 2023 on Tuesday 7 May 2024.
Sarah Howell, Chief Executive Officer, and Manjit Rahelu, Chief Business Officer, will host an in-person briefing for analysts on the day of the results. There will also be a live webcast and conference call with a Q&A session.
For more details or to attend the briefing, please contact [email protected]
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
|
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: [email protected] |
|
|
|
|
Susan Lowther, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: [email protected] |
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
|
WG Partners LLP (Financial Advisor) Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang
|
Tel: +44 (0) 203 705 9321 |
|
ICR Consilium |
|
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com